Rexahn: Corporate Presentation (Rexahn Pharmaceuticals, Inc) - Sep 13, 2014 - "Archexin®: Phase I and Phase IIa Clinical trials (completed)"; "Phase I (Cancer patients with solid tumors)"; "MTD was 250 mg/m2/d in patients with an advanced cancer after up to two cycles of treatment"; "The dose limiting toxicity was Grade 3 fatigue; no significant hematological abnormalities"
P1 data • Oncology
|